Thorsten G.
- Country
- Germany
- Department
- Institut fuer Klinische Krebsforschung (IKF)
Research Overview
- Sotorasib and Combination Therapy Versus Standard Chemotherapy in Treatment-Naïve Patients with KRAS p.G12C-Mutated Metastatic Colorectal Cancer
- Efficacy and Safety of PF-08634404 and Combination Therapy Versus Bevacizumab and Combination Therapy in Treatment-Naïve Participants With Metastatic Colorectal Cancer
- Efficacy and Safety of PF-08634404 Plus Combination Therapy Versus Pembrolizumab Plus Combination Therapy in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 242 of 485 partner sites.
Specializations
Lung Cancer Immunotherapy and Targeted Therapy
Focus on advanced and metastatic lung malignancies, integrating immune checkpoint inhibition with kinase‑targeted agents.
- ALK‑positive Non‑Small Cell Lung Cancer
- EGFR‑mutated Non‑Small Cell Lung Cancer
- PD‑L1‑positive Non‑Small Cell Lung Cancer
- Small Cell Lung Cancer
- SMARCA4‑deficient Tumor
Research conducted at Institut für Klinische Krebsforschung IKF GmbH and Krankenhaus Nordwest GmbH in Frankfurt, Germany.
Gastrointestinal Oncology
Investigation of adenocarcinomas of the stomach, esophagus, and colon, emphasizing biomarker‑driven combination regimens.
- HER2‑positive Gastric Cancer
- FGFR2b‑overexpressing Gastroesophageal Junction Adenocarcinoma
- BRAF‑mutant Colorectal Cancer
- KRAS G12C Colorectal Cancer
- MSI‑high Colorectal Cancer
Studies leverage the clinical trial network of two Frankfurt‑based sites.
Hepatobiliary and Liver Malignancies
Exploration of primary liver cancer and biliary tract neoplasms, targeting molecular alterations and immunotherapeutic strategies.
- Hepatocellular Carcinoma
- Intrahepatic Cholangiocarcinoma with IDH1 Mutation
- Extrahepatic Cholangiocarcinoma
- Biliary Tract Cancer
- FGFR‑altered Cholangiocarcinoma
Collaborative efforts integrate translational biomarkers across both affiliated institutions.
Genitourinary Oncology
Targeted and hormonal approaches for prostate, bladder, and renal malignancies, focusing on advanced disease settings.
- Metastatic Castration‑Sensitive Prostate Cancer
- Metastatic Castration‑Resistant Prostate Cancer
- Metastatic Clear Cell Renal Cell Carcinoma
- Urothelial Bladder Cancer
- FGFR‑altered Urothelial Carcinoma
Clinical programs are coordinated through the two Frankfurt research sites.
Hematologic and Rare Malignancies
Addressing lymphoid, plasma‑cell, and rare solid tumors with innovative immune and targeted modalities.
- Hodgkin Lymphoma
- Indolent B‑cell Non‑Hodgkin Lymphoma
- Multiple Myeloma
- SMARCA4‑deficient Tumor
- Rare Sarcoma Subtypes
Research activities are integrated within the broader oncology portfolio at both institutions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.